- $285.48m
- $258.33m
- $83.57m
- 87
- 19
- 89
- 71
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 393.63 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 10.03 | ||
| Price to Tang. Book | 10.22 | ||
| Price to Free Cashflow | 40.96 | ||
| Price to Sales | 3.42 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -16.3% | ||
| Return on Equity | -17.29% | ||
| Operating Margin | -6.7% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 46.29 | 59.26 | 67.45 | 72.05 | 83.57 | 97.57 | 114.37 | 21.5% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Chromadex Corp. is a global bioscience company. The Company is engaged in research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. Its segments include Consumer Products, Ingredients and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the Company's proprietary ingredients, commercialized as Tru Niagen, directly to consumers and distributors. The Ingredients segment develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The Ingredients segment provides Niagen in ingredient form to its strategic partners. The Analytical Reference Standards and Services segment offers the supply of phytochemical reference standards and other research and development services.
Directors
- Frank Jaksch CHM (52)
- Robert Fried CEO (61)
- Kevin Farr CFO (63)
- Fadi Karam CMO
- Lisa Harrington GCN (53)
- Kurt Gustafson LED (53)
- Jeffrey Baxter IND (59)
- Stephen Block IND (76)
- Caroline Levy IND (58)
- Gary Ng IND (49)
- Steven Rubin IND (61)
- Wendy Yu IND (45)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- June 19th, 2008
- Public Since
- June 25th, 2007
- No. of Shareholders
- 40
- No. of Employees
- 106
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 75,523,785
- Address
- 10900 Wilshire Blvd, Suite 600, LOS ANGELES, 90024
- Web
- https://chromadex.com/default.aspx
- Phone
- +1 3103886706
- Auditors
- Marcum LLP
Upcoming Events for CDXC
Q1 2024 Chromadex Corp Earnings Call
Chromadex Corp Annual Shareholders Meeting
Chromadex Corp Annual Shareholders Meeting
Q2 2024 Chromadex Corp Earnings Release
Similar to CDXC
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Chromadex share price?
As of Today at 19:05 UTC, shares in Chromadex are trading at $3.78. This share price information is delayed by 15 minutes.
How has the Chromadex share price performed this year?
Shares in Chromadex last closed at $3.78 and the price had moved by +180% over the past 365 days. In terms of relative price strength the Chromadex share price has outperformed the S&P500 Index by +125.86% over the past year.
What are the analyst and broker recommendations for Chromadex?
The overall consensus recommendation for Chromadex is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Chromadex dividend yield?
Chromadex does not currently pay a dividend.
Does Chromadex pay a dividend?
Chromadex does not currently pay a dividend.
When does Chromadex next pay dividends?
Chromadex does not currently pay a dividend.
How do I buy Chromadex shares?
To buy shares in Chromadex you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Chromadex?
As of the previous close price of $3.78, shares in Chromadex had a market capitalisation of $285.48m.
Where are Chromadex shares listed?
Here are the trading details for Chromadex:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: CDXC
What kind of share is Chromadex?
Based on an overall assessment of its quality, value and momentum Chromadex is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Chromadex share price forecast for 2024?
The analyst consensus target price for shares in Chromadex is $6.47. That is 71.16% above the last closing price of $3.78.
Analysts covering Chromadex currently have a consensus Earnings Per Share (EPS) forecast of -$0.01 for the next financial year.
What is the trend in the Chromadex share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Chromadex. Over the past six months, its share price has outperformed the S&P500 Index by +117.46%.
As of the last closing price of $3.78, shares in Chromadex were trading +102.62% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Chromadex PE Ratio?
The Chromadex PE ratio based on its reported earnings over the past 12 months is 393.63. The shares last closed at $3.78.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Chromadex?
Chromadex's management team is headed by:
- Frank Jaksch - CHM
- Robert Fried - CEO
- Kevin Farr - CFO
- Fadi Karam - CMO
- Lisa Harrington - GCN
- Kurt Gustafson - LED
- Jeffrey Baxter - IND
- Stephen Block - IND
- Caroline Levy - IND
- Gary Ng - IND
- Steven Rubin - IND
- Wendy Yu - IND